×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agendas
Rare Diseases and Subgroups Defined by Tumor Evolution: Common Themes and Challenges
Session Chair(s)
Robert A. Beckman, MD
Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics
Georgetown University Medical Center, United States
Rare diseases present a unique challenge for developing evidence to support new therapies. Molecular subgroups of cancer define equally small populations, which also evolve over time. Clinical development and treatment challenges will be discussed.
Learning Objective : Define the challenges of producing clinical evidence for new therapies in rare diseases; Describe the role of intratumoral heterogeneity and genetic dynamics in determining optimal treatment strategies for cancer; Identify the strengths and limitations of the current personalized medicine paradigm for cancer.
Speaker(s)
Nature and Extent of Evidence Required for Approval in Rare Diseases
Jeffrey Schwartz, PhD, MS
Pfizer Inc, United States
Senior Director
Intratumoral Heterogeneity and Tumor Evolution Creates Dynamic Subgroups in Cancer
Robert A. Beckman, MD
Georgetown University Medical Center, United States
Professor of Oncology and of Biostatistics, Bioinformatics, and Biomathematics
Considerations from a Regulatory Perspective
Grant Williams, MD
Wms Cancer Drug Consulting, United States
President `
Have an account?
Ways to register
Registration override should work.